MedPath

cGMP: Metabolism and Appetite Modulation

Not Applicable
Not yet recruiting
Conditions
Healthy
Registration Number
NCT06794515
Lead Sponsor
Universidade Nova de Lisboa
Brief Summary

Phenylketonuria is an inborn error of phenylalanine metabolism. Although the phenylalanine-restricted diet is recognized as the mainstay of therapy, little is known about the impact of protein substitutes on the metabolism of patients with phenylketonuria.

Therefore, the aim of this project is to study the impact of acute ingestion of casein glycomacropeptide supplemented with amino acids (cCGMP-AAs) alone or in combination with two different meals on amino acid absorption kinetics, glycaemic and insulinemic response, and on acute markers of appetite control.

The main findings of this project will bring new insights into the dietary management of these patients, which may lead to improvements in protein substitutes formulations.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
15
Inclusion Criteria
  • Men or women
  • Adults (age ≥ 18 years)
  • Body Mass Index (BMI) between 18.5-25.0 kg/m2
  • Filling informed consent
Exclusion Criteria
  • Clinically significant illness
  • Have changed frequency, duration, or intensity of physical activity in the last month
  • Taking protein supplements
  • Pregnant or breastfeeding
  • Smoking and drug use

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Changes in the iAUC (mmol/L*min) for total amino acids180 minutes

Total amino acids will be measured in fasting and every 30 minutes up to 180 minutes. The iAUC (mmol/L\*min) for amino acids will be calculated based on the concentration curve following consumption of the test meal.

Changes in the iAUC (pmol/L*min) for glucagon-like peptide-1 (GLP-1)180 minutes

GLP-1 will be measured in fasting and every 30 minutes up to 180 minutes. The iAUC (pmol/L\*min) for GLP-1 will be calculated based on the concentration curve following consumption of the test meal.

Changes in the iAUC (pmol/L*min) for Cholecystokinin (CCK)180 minutes

CCK will be measured in fasting and every 30 minutes up to 180 minutes. The iAUC (pmol/L\*min) for CCK will be calculated based on the concentration curve following consumption of the test meal.

Changes in the iAUC (pmol/L*min) for peptide YY (PYY)180 minutes

PYY will be measured in fasting and every 30 minutes up to 180 minutes. The iAUC (pmol/L\*min) for PYY will be calculated based on the concentration curve following consumption of the test meal.

Changes in the iAUC (pmol/L*min) for Gastric inhibitory polypeptide (GIP)180 minutes

GIP will be measured in fasting and every 30 minutes up to 180 minutes. The iAUC (pmol/L\*min) for GIP will be calculated based on the concentration curve following consumption of the test meal.

Secondary Outcome Measures
NameTimeMethod
Changes in glucose180 minutes

Glucose will be measured in fasting and every 30 minutes up to 3 hours. The iAUC (mmol/L\*min) for glucose will be calculated based on the concentration curve following consumption of the test meal.

Changes in insulin180 minutes

Insulin will be measured in fasting and every 30 minutes up to 3 hours. The iAUC (mmol/L\*min) for insulin will be calculated based on the concentration curve following consumption of the test meal.

Changes in C-peptide180 minutes

C-peptide will be measured in fasting and every 30 minutes up to 3 hours. The iAUC (mmol/L\*min) for C-peptide will be calculated based on the concentration curve following consumption of the test meal.

Trial Locations

Locations (1)

NOVA Medical School|Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisboa,

🇵🇹

Lisboa, Portugal

© Copyright 2025. All Rights Reserved by MedPath